Volume growth from AMGN's key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Amgen’s next-generation cholesterol drug has shown it can reverse the build up of plaque build-up in coronary arteries which can lead to a heart attack or stroke. The company’s Repatha ...

Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.

Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its Covid antibody cocktail as ...

The drug made $1.63 billion in sales last year ... though did not say that there was any direct connection to Repatha. The spokesperson added that this is an “extension of our LDL-C testing ...

Dr. Kim has contributed to the development and/or approval of multiple drugs including Givlaari ... (mavacamten), Corlanor (ivabradine), and Repatha (evolcumab). Dr. Kim is a board-certified ...

Other signs of renewed pharma innovation include the approval by the European Commission this week of Amgen’s Repatha drug, which was shown in clinical trials to reduce “bad cholesterol” by ...

Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs ...

Among Amgen’s cardiovascular products is Repatha, or evolocumab, which was originally approved by the Food and Drug Administration (FDA) in 2015 to treat high levels of LDL-C. The pharma has also been ...

Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs ...

However, GLP-1 drugs for weight loss significantly boosted ... with ten products achieving double-digit volume growth, including Repatha, TEZSPIRE, and EVENITY. Additionally, the acquisition ...